Orgenesis (ORGS) – Press Releases
-
Orgenesis Provides Year End Business Update
-
Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility
-
Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference
-
Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes
-
Orgenesis Inc. Announces $2.3 Million Private Placement
-
Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing
-
Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic
-
Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM
-
Orgenesis Provides Business Update for the Third Quarter of 2023
-
Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering
-
Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding
-
Orgenesis Announces Withdrawal of Proposed Public Offering
-
Orgenesis Announces Proposed Underwritten Public Offering
-
CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States
-
Cell and Gene Therapy Industry Pioneer & GMP Expert, Gerhard Bauer, Joins Orgenesis Business, Octomera, to Drive Continued Expansion of POCare Facilities and Service Support
-
Orgenesis Provides Business Update for Second Quarter of 2023
-
Orgenesis Schedules Second Quarter 2023 Business Update Conference Call
-
Orgenesis Appoints Finance Veteran Elliot Maltz as its Chief Financial Officer
-
Orgenesis Announces Name Change of Morgenesis Business Unit to Octomera
-
Orgenesis and University of California, Davis Sign Partnership Agreement for Rollout of Cell and Gene Therapy Mobile Processing Units and Labs Throughout California
-
Claudia Zylberberg Appointed as Independent Board Member of POCare Business Subsidiary of Orgenesis
-
Orgenesis Academy Graduates First Class of Cell and Gene Therapy Experts from theraCell Laboratories-backed Master’s Program
-
Orgenesis to Participate in Benchmark’s 3rd Annual Healthcare House Call Virtual 1x1 Investor Conference on May 23, 2023
-
Orgenesis Announces Collaboration Agreement with SCTbio to Expand POCare Sites in the Czech Republic and Enhance Capabilities for the Production of Lentivirus Vectors
-
Orgenesis Provides Business Update for the First Quarter of 2023 and Reports Continued Progress on its POCare Strategy
-
Orgenesis Secures an Additional $5 Million Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Service Subsidiary
-
Orgenesis CEO Vered Caplan Featured in Keynote Series at INTERPHEX Conference to Discuss Innovations in Cell & Gene Therapy Manufacturing
-
Orgenesis Reports 98% Year-Over-Year Increase in Revenue to $13.6 Million for the Fourth Quarter of 2022
-
Orgenesis Schedules Fourth Quarter 2022 Business Update Conference Call
-
Orgenesis Signs MOU with University of California, Davis to Develop a Collaboration Agreement to Deploy Cell and Gene Therapy Mobile Processing Units and Labs Across California
-
Orgenesis Inc. Announces Closing of $3.7 Million Registered Direct Offering
-
Orgenesis Inc. Announces Pricing of $3.7 Million Registered Direct Offering
-
Orgenesis and Kurve Therapeutics Announce Pre-Clinical Study Results for a Cell-Based Oncolytic Virus Bearing Product Demonstrating Over 50% Reduction in a Murine Glioblastoma Model
-
Orgenesis Achieves Revenue of $8.0 Million for the Third Quarter of 2022
-
Orgenesis Schedules Third Quarter 2022 Business Update Conference Call
-
Orgenesis Secures up to $50 Million Subsidiary-Level Investment from Metalmark Capital to Accelerate Growth of Point-of-Care Services
-
Orgenesis Achieves Revenue of $7.2 Million for the Second Quarter of 2022
-
Orgenesis Schedules Second Quarter 2022 Business Update Conference Call
-
Orgenesis Achieves Revenue of $7.2 Million for the First Quarter of 2022
-
Orgenesis Led Consortium Awarded €4M European Innovation Council Pathfinder Grant
-
Orgenesis Inc. Announces $14.8 Million Private Placement
-
Orgenesis Reports Revenue Growth of 364% for 2021 and Provides Business Update
-
Orgenesis Schedules 2021 Fiscal Year Business Update Conference Call
-
Orgenesis reaches next milestone in collaboration with Hospital Infantil Universitario Niño Jesús in Madrid
-
Orgenesis and Johns Hopkins University expand POCare in Maryland through creation of the Maryland Center for Cell Therapy Manufacturing
-
Orgenesis and Theracell Joint Venture to Receive up to €32 Million From Greek Government to Accelerate Rollout of POCare Centers and Deployment of OMPULs
-
Orgenesis Announces Collaboration Agreement with Tel Aviv Sourasky Medical Center to Advance Point-of-Care Development and Commercialization of Cell and Gene and Therapies
-
Orgenesis Reports 425% Increase in Revenue for the Third Quarter of 2021 Compared to Same Period Last Year
-
Orgenesis Schedules Third Quarter 2021 Business Update Conference Call
-
Orgenesis Announces Collaboration Agreement with Savicell to License and Deploy its ImmunoBiopsy™ Platform
Back to ORGS Stock Lookup
